Michael T. Flavin is the Corporate Strategy Advisor at SELAGINE, INC. Dr. Flavin received his B.S. degree in chemistry from Notre Dame and his Ph.D. degree in medicinal chemistry from University of Illinois at Chicago.  After completing his postdoctoral fellowship at Harvard in synthetic organic chemistry, he was a Senior Research Scientist at Baxter prior to founding MediChem Life Sciences. In 2000, MediChem completed a $54M IPO with UBS as the lead underwriter. MediChem was acquired in 2002 by deCODE genetics (NASDAQ:DCGN) to build a complete “gene map to drug” business model. He is the Managing Director of Flavin Ventures, an early stage venture creation firm focused on creating, financing and developing biotechnology companies. Dr. Flavin is also Visiting Research Professor at the University of Illinois at Chicago College of Medicine. At SELAGINE, Dr. Flavin will advise regarding a variety of high-level decisions surrounding corporate structure and FDA IND and Clinical Trial strategy.